Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05302999 · ClinicalTrials.gov registry record · Phase 4
Feasibility of Early Gabapentin as an Intervention for Neurorecovery
A Phase 4 study of Spinal Cord Injuries, sponsored by MetroHealth Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05302999 is a Phase 4 study of Spinal Cord Injuries that is actively recruiting participants, run by MetroHealth Medical Center. The registered enrollment target is 42 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05302999, a Phase 4 study of Spinal Cord Injuries, is actively recruiting participants, sponsored by MetroHealth Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin
Study Locations (1)
Ohio
- MetroHealth Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05302999
The ClinicalTrials.gov registry entry for NCT05302999 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (31% lower). The listed sponsor is MetroHealth Medical Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05302999 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05302999 about?
NCT05302999 is a clinical study titled "Feasibility of Early Gabapentin as an Intervention for Neurorecovery". The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goa...
What is the current status of trial NCT05302999?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2022-03-14. Estimated completion is 2026-08-31.
What conditions does trial NCT05302999 study?
This clinical trial studies the following conditions: Spinal Cord Injuries.
What interventions are being tested in trial NCT05302999?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT05302999?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05302999 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
RECRUITING · NA
-
Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury
RECRUITING · NA
-
Transcutaneous Spinal Stimulation and Exercise for Locomotion
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.